Moreover, chromatin modifiers are already recognized as a cancer therapy target and clinical trials for the treatment of MLL1/KMT2A-fusion leukemia provide evidence for the development of drugs targeting the members of KMT2 family [19]. Here, KMT2A is linked to cancer.